Rallybio (NASDAQ:RLYB) is a biotechnology firm dedicated to identifying and accelerating the development of transformative therapies for patients with severe and rare diseases. Rallybio's operations focus on advancing a diverse portfolio of promising therapeutic candidates through clinical trials, with the objective of addressing unmet medical needs in areas where treatment options are limited or non-existent. The company's projects range from preclinical discovery phases to advanced clinical trials, leveraging cutting-edge technologies and strategic collaborations to speed up the development process. Rallybio aims to improve the lives of patients by delivering innovative treatments that can offer significant health benefits and enhance quality of life.